Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lactobacillus acidophilus AD031
- Development stage
- Preclinical
- Lead developer
- BIFIDO
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Lactobacillus acidophilus AD031 is a probiotic strain that has been investigated for various health benefits. [6] In clinical studies, it has shown efficacy, often in combination with other probiotic strains, in reducing the duration of diarrhea in infants with rotavirus infection, alleviating symptoms of irritable bowel syndrome (IBS), and preventing the development of eczema in high-risk infants. [1, 4, 5] Preclinical studies in mice suggest it has anti-obesity effects by reducing liver triglycerides and improving hepatic steatosis, and can suppress allergic responses in food allergy models. [2, 6] The mechanism of action is believed to involve modulation of the host's immune system. [6] For instance, it can influence cytokine production by dendritic cells, decrease pro-inflammatory markers, and increase anti-inflammatory markers like TGF-β. [3]
- Other names
- L. acidophilus AD031
Beyond the preview
Go deeper on Lactobacillus acidophilus AD031.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lactobacillus acidophilus AD031.